The pigmented purpuric dermatoses are a group of chronic diseases of mostly unknown etiology that have a very distinctive clinical appearance. They are characterized by extravasation of erythrocytes in the skin with marked hemosiderin deposition.
A number of clinical patterns of pigmented purpuric dermatoses or capillaritis are recognized that may represent different presentations of the same disorder; however, this generally does not influence the treatment or the prognosis. They all show a similar histologic appearance. The term pigmented purpuric dermatoses includes Schamberg disease (ie, progressive pigmentary dermatosis), purpura annularis telangiectodes (Majocchi disease),[1] lichen aureus, itching purpura, eczematidlike purpura of Doucas and Kapetanakis, and the pigmented purpuric lichenoid dermatosis of Gougerot and Blum.[2, 3] Many consider itching purpura and eczematidlike purpura to be variants of Schamberg disease.
The etiology is unknown. Several cofactors have been reported that appear to influence disease presentation, including hypertension, diabetes mellitus, venous stasis, strenuous exercise, gravitational dependency, capillary fragility, focal infections, and chemical ingestion.[4] Histologically, a perivascular T-cell lymphocytic infiltrate is centered on the superficial small blood vessels of the skin, which show signs of endothelial cell swelling and narrowing of the lumen. Extravasation of red blood cells with marked hemosiderin deposition in macrophages is also found, and a rare granulomatous variant of chronic pigmented dermatosis has been reported.[5]
Early onset disease may sometimes be associated with platelet-storage defects.[6]
The cause of pigmented purpuric dermatoses is unknown. Rare familial cases of Schamberg disease and Majocchi disease have been reported in the literature, implying a genetic cause in a minority of patients.
United States
Pigmented purpuric dermatoses are common.
International
During a 10-month period, the author's United Kingdom hospital-based dermatology practice, which serves a population of 300,000 persons, identified only 10 such cases. Five cases were diagnosed as having lichen aureus, and the remainder had more extensive capillaritis.
Persons of any race can be affected by pigmented purpuric dermatoses.
Pigmented purpuric dermatoses usually occur more frequently in men than in women. However, purpura annularis telangiectodes of Majocchi is seen more frequently in women.
Schamberg disease may occur in persons of any age.
Itching purpura and the dermatosis of Gougerot and Blum mainly affect middle-aged men.
Lichen aureus and Majocchi disease are predominantly diseases of children or young adults.
Many lesions persist or extend with time. Most eventually resolve spontaneously. Typically, the condition is asymptomatic, but pruritus may sometimes be a prominent feature in some cases, especially in patients with itching purpura or eczematidlike purpura of Doucas and Kapetanakis. These diseases have no systemic findings.
Patients complain about the appearance of their skin.
In Schamberg disease, irregular plaques and patches of orange-brown pigmentation develop on the lower limbs. The lesions are chronic and persist for years. With time, many of the lesions tend to extend and may become darker brown in color, but some may spontaneously clear.
In itching purpura, the lesions are much more extensive, and patients typically complain of severe pruritus.
The hallmark of a pigmented purpuric dermatosis is its characteristic orange-brown, speckled, cayenne pepper–like discoloration. The lower limbs are affected in Schamberg disease, whereas itching purpura is characterized by more generalized skin involvement.
In lichen aureus, the eruption is usually a solitary lesion or a localized group of golden brown lesions that may affect any part of the body; however, the leg is the most commonly affected area. Linear or segmental forms of lichen aureus have been reported.
Majocchi disease is characterized by small annular plaques of purpura that contain prominent telangiectasias.
Pigmented purpura with lichenoid-type skin change is yet another clinical variant, which Gougerot and Blum first reported. Lesions appear similar to those of Schamberg disease in association with red-brown lichenoid papules.
Note the clinical images below.
Pigmented purpuric dermatoses must be distinguished from early cutaneous T-cell lymphoma, purpuric clothing dermatitis, stasis pigmentation, scurvy, leukocytoclastic vasculitis, purpuric generalized lichen nitidus,[7] and drug hypersensitivity reactions (eg, allergy to rituximab, carbamazepine, meprobamate, bufexamac, chlordiazepoxide, furosemide, nitroglycerin, vitamin B-1, or injection with medroxyprogesterone acetate).[8, 9, 10, 11, 12, 13, 14]
A case of glipizide-induced pigmented purpuric dermatosis has been reported.[15]
Topical fluorouracil and eutectic mixture of local anesthetics (EMLA) have been implicated in a pigmented purpuric dermatitislike skin eruption.
Pharmacologically induced regressed Kaposi sarcoma lesions may be misdiagnosed clinically and histologically as pigmented purpuric dermatitis.[16]
Buckthal-McCuin and Mutasim described macular arteritis mimicking pigmented purpuric dermatosis.[17]
Vasculitis
A complete blood cell count is necessary to exclude thrombocytopenia, and coagulation screening helps to exclude other possible causes of purpura.
Dermoscopy has been reported to be a useful tool for assisting the clinical diagnosis of pigmented purpuric dermatoses.[18, 19]
Capillary fragility may be assessed by the Hess test.
A skin biopsy helps to confirm the diagnosis of a pigmented purpuric eruption and aids in excluding cutaneous T-cell lymphoma, which in its early stages may closely mimic a pigmented purpuric dermatitis both clinically and histologically.[20]
Histologically, a perivascular infiltrate of lymphocytes and macrophages is centered on the superficial small blood vessels of the skin. Signs of endothelial cell swelling and narrowing of lumina may be seen, as demonstrated in the image below.
The infiltrate is composed of predominantly CD4+ lymphocytes along with occasional CD1a+ dendritic cells. Plasma cells and neutrophils are occasionally present; the latter is not uncommon in lesions of itching purpura. Extravasation of red blood cells with marked hemosiderin deposition in macrophages is typically seen, as demonstrated in the image below. However, the degree of hemosiderin deposition may be variable, and it can be minimal in early lesions of itching purpura.[21]
Histochemical staining with Perls stain and Fontana-Masson stain, to demonstrate iron (hemosiderin) and exclude melanin pigment respectively, may be helpful. Hemosiderin deposition in the dermis is more superficial in pigmented purpuric dermatitis than that seen in stasis dermatitis, which is a useful differentiating feature. Mild epidermal spongiosis and exocytosis of lymphocytes may be seen in all variants except lichen aureus, which, in general, tends to show a bandlike infiltrate separated from the epidermis by a thin rim of uninvolved collagen.
Kerns et al described an unusual variant of pigmented purpuric dermatoses, granulomatous pigmented purpura, in a 42-year-old white woman, and Wong et al reported 2 cases of a similar variant.[22, 23]
No medical intervention is of consistent benefit for the treatment of the pigmented purpuric dermatoses.
Pruritus may be alleviated by the use of topical corticosteroids and antihistamines.
Associated venous stasis should be treated by compression hosiery.
Prolonged leg dependency should be avoided.
The use of narrowband UVB and psoralen plus UVA have shown to be effective treatments for some patients with pigmented purpuric dermatoses.[24, 25, 26, 27, 28]
Tamaki et al reported successful treatment of pigmented purpuric dermatoses using griseofulvin.[29] Treatment with oral cyclosporin has also been successful.[30]
Successful therapy with ascorbic acid (500 mg twice daily) and rutoside (50 mg twice daily) has also been reported.[31] Anecdotal data exist for calcineurin-inhibitors, colchicine, pentoxifylline, immunosuppressants, ultraviolet therapy, and laser therapy.[32]
A follow-up consultation is required for cases in which initially diagnostic uncertainty exists, particularly to exclude cutaneous lymphoma.
Topical steroid treatment if used long term should be monitored for the possible development of adverse effects.
The goals of pharmacotherapy are to reduce morbidity and to prevent complications.
These agents are effective in relieving pruritus. These agents have anti-inflammatory properties and cause profound and varied metabolic effects. They modify the body's immune response to diverse stimuli.
Hydrocortisone topical is an adrenocorticosteroid derivative suitable for application to skin or external mucous membranes. It has mineralocorticoid and glucocorticoid effects, resulting in relief of pruritus.
Clobetasol is a class I superpotent topical steroid; it suppresses mitosis and increases the synthesis of proteins that decrease inflammation and cause vasoconstriction.
Betamethasone topical is for inflammatory dermatoses responsive to steroids. It decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability.
These agents may treat itching by blocking effects of endogenously released histamine.
Diphenhydramine is for symptomatic relief of pruritus caused by the release of histamine in inflammatory reactions.
Overview
What are pigmented purpuric dermatoses?
What causes pigmented purpuric dermatoses?
What causes pigmented purpuric dermatoses?
Are pigmented purpuric dermatoses common in the US?
What is the international incidence of pigmented purpuric dermatoses?
Do pigmented purpuric dermatoses have a racial predilection?
Are pigmented purpuric dermatoses more common in males or females?
Do pigmented purpuric dermatoses have an age predilection?
What is the prognosis of pigmented purpuric dermatoses?
Presentation
How do pigmented purpuric dermatoses present?
How are the variations of pigmented purpuric dermatoses characterized?
DDX
What are the diagnostic considerations of pigmented purpuric dermatoses?
What are the differential diagnoses for Pigmented Purpuric Dermatosis?
Workup
Which lab studies are indicated in the workup of pigmented purpuric dermatoses?
What is the role of dermoscopy in the clinical diagnosis of pigmented purpuric dermatoses?
What other tests may be indicated in the workup of pigmented purpuric dermatoses?
Which procedures are used to confirm the diagnosis of pigmented purpuric dermatoses?
What are the histologic findings of pigmented purpuric dermatoses?
Treatment
How are pigmented purpuric dermatoses treated?
When is a follow-up consultation indicated in the treatment of pigmented purpuric dermatosis?
Medications
What are the goals of drug treatment for pigmented purpuric dermatoses?